Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes
Year: 2020
Type: article
Abstract: private insurance but whose data were not in the Optum database.Second, the imputed insulin price did not account for manufacturer rebates.Third, the claims data used may have had inaccuracies.Although the findings in this study contradict the view that insulin cost-sharing is excessive for many privately insured patients, 2 monthly out-of-pocket payments may be burdensome for low-income individuals.Nevertheless, the data suggest that privately insured patients have been relatively shielded from insulin price increases and that commercial health insurers have accommodated higher insulin prices by increasing premiums or deductibles for all members.6
Source: JAMA Internal Medicine
Authors: Kao-Ping Chua, Joyce M. Lee, Rena M. Conti
Institutions: University of Michigan, Michigan Medicine, Boston University
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
Funders: University of Michigan, Centers for Disease Control and Prevention, National Institute on Drug Abuse, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Using Default Opioid Prescription Settings to Limit Excessive Opioid Prescribing to Adolescents and Young Adults, Target self-regulation to promote adherence and health behaviors in children, Michigan Center for Diabetes Translational Research, Diabetes Research and Engagement through Advanced Multilevel Science Center for Diabetes Translational Research (DREAMS-CDTR)
OpenAlex ID: W3030743744